scispace - formally typeset
R

Renhua Huang

Researcher at Shanghai Jiao Tong University

Publications -  6
Citations -  112

Renhua Huang is an academic researcher from Shanghai Jiao Tong University. The author has contributed to research in topics: Tumor progression & Radioresistance. The author has an hindex of 3, co-authored 5 publications receiving 48 citations. Previous affiliations of Renhua Huang include Soochow University (Suzhou).

Papers
More filters
Journal ArticleDOI

AHIF promotes glioblastoma progression and radioresistance via exosomes

TL;DR: The present study is the first to establish thatAHIF promotes glioblastoma progression and radioresistance via exosomes, which suggests that AHIF is a potential therapeutic target for GBM.
Journal ArticleDOI

The LGMN pseudogene promotes tumor progression by acting as a miR-495-3p sponge in glioblastoma.

TL;DR: It is found that a novel LGMN pseudogene (LGM NP1) was upregulated in glioblastoma (GBM) tissues and high LGMNP1 expression in GBM cells enhanced proliferation and invasion and CeRNA-mediated miRNA sequestration might be a novel therapeutic strategy in G BM.
Journal ArticleDOI

Circular RNA circLGMN facilitates glioblastoma progression by targeting miR-127-3p/LGMN axis

TL;DR: In this paper, the authors found that circLGMN was the most abundantly expressed circRNA derived from Legumain and showed that LGMN overexpression promoted GBM cell proliferation and enhanced cell invasion.
Journal ArticleDOI

Upregulated AHIF-mediated radioresistance in glioblastoma.

TL;DR: In this article, the antisense transcript of hypoxia-inducible factor-1α (AHIF) was upregulated in glioblastoma multiforme (GBM) cells after radiotherapy.
Journal ArticleDOI

Regulation of the macrophage-related inflammatory micro-environment for atherosclerosis treatment and angiogenesis via anti-cytokine agents

TL;DR: In vitro mechanistic studies indicated that the MSNs@anti-IL-1β can regulate the macrophage-related inflammatory microenvironment, promote the viability of vascular endothelial cells (vECs), and reduce proliferation and phenotypic switching of vascular smooth muscle cells ( vSMCs) and taken together, these MSNs affording the sustained release of anti-cytokine agents may have broad implications for the clinical management of the AS.